REFERENCES
1. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13.
2. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90:3710-4.
3. Culligan KG, Mackey AJ, Finn DM, Maguire PB, Ohlendieck K. Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Int J Mol Med. 1998;2:639-48.
4. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet. 1993;3:283-91.
5. Górecki DC, Monaco AP, Derry JM, Walker AP, Barnard EA, Barnard PJ. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum Mol Genet. 1992;1:505-10.
6. Klietsch R, Ervasti JM, Arnold W, Campbell KP, Jorgensen AO. Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. Circ Res. 1993;72:349-60.
7. Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet. 1984;66:17-40.
8. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291-329.
9. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919-28.
10. Birnkrant DJ, Bushby K, Bann CM, et al. DMD care considerations working group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251-67.
11. McNally EM, Kaltman JR, Benson DW, et al. Working group of the national heart; lung; and blood institute; parent project muscular dystrophy. Contemporary cardiac issues in Duchenne muscular dystrophy. Working group of the national heart, lung, and blood institute in collaboration with parent project muscular dystrophy. Circulation. 2015;131:1590-8.
12. Miller RG, Hoffman EP. Molecular diagnosis and modern management of Duchenne muscular dystrophy. Neurologic Clinics. 1994;12:699-725.
13. Rio-Pertuz G, Morataya C, Parmar K, Dubay S, Argueta-Sosa E. Dilated cardiomyopathy as the initial presentation of Becker muscular dystrophy: a systematic review of published cases. Orphanet J Rare Dis. 2022;17:194.
14. Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20:18168-84.
15. Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and safety of Vamorolone vs. placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol. 2022;79:1005-14.
16. Deconinck AE, Rafael JA, Skinner JA, et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997;90:717-27.
17. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 1997;90:729-38.
18. Young CS, Mokhonova E, Quinonez M, Pyle AD, Spencer MJ. Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR/Cas9 gene editing therapy. J Neuromuscul Dis. 2017;4:139-45.
19. Sacco A, Mourkioti F, Tran R, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell. 2010;143:1059-71.
20. Mourkioti F, Kustan J, Kraft P, et al. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol. 2013;15:895-904.
21. Chang AC, Ong SG, LaGory EL, et al. Telomere shortening and metabolic compromise underlie dystrophic cardiomyopathy. Proc Natl Acad Sci U S A. 2016;113:13120-5.
22. Chey YCJ, Corbett MA, Arudkumar J, Piltz SG, Thomas PQ, Adikusuma F. CRISPR-mediated megabase-scale transgene de-duplication to generate a functional single-copy full-length humanized DMD mouse model. BMC Biol. 2024;22:214.
23. Sugihara H, Kimura K, Yamanouchi K, et al. age-dependent echocardiographic and pathologic findings in a rat model with Duchenne muscular dystrophy generated by CRISPR/Cas9 genome editing. Int Heart J. 2020;61:1279-84.
24. Sui T, Lau YS, Liu D, et al. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9. Dis Model Mech. 2018:11.
25. Cooper BJ, Winand NJ, Stedman H, et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature. 1988;334:154-6.
26. Kornegay JN. The golden retriever model of Duchenne muscular dystrophy. Skelet Muscle. 2017;7:9.
27. Guo LJ, Soslow JH, Bettis AK, et al. Natural history of cardiomyopathy in adult dogs with golden retriever muscular dystrophy. J Am Heart Assoc. 2019;8:e012443.
28. Klymiuk N, Blutke A, Graf A, et al. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet. 2013;22:4368-82.
29. Stirm M, Klymiuk N, Nagashima H, Kupatt C, Wolf E. Pig models for translational Duchenne muscular dystrophy research. Trends Mol Med. 2024;30:950-64.
30. Chen Y, Zheng Y, Kang Y, et al. Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet. 2015;24:3764-74.
31. Ren S, Fu X, Guo W, et al. Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy. Cell. 2024;187:6669-6686.e16.
32. Lambert MR, Spinazzola JM, Widrick JJ, et al. PDE10A inhibition reduces the manifestation of pathology in DMD zebrafish and represses the genetic modifier PITPNA. Mol Ther. 2021;29:1086-101.
33. Hightower RM, Reid AL, Gibbs DE, et al. The SINE compound KPT-350 blocks dystrophic pathologies in DMD zebrafish and mice. Mol Ther. 2020;28:189-201.
34. Wasala NB, Chen SJ, Duan D. Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine. Expert Opin Drug Discov. 2020;15:443-56.
35. Ellwood RA, Hewitt JE, Torregrossa R, et al. Mitochondrial hydrogen sulfide supplementation improves health in the C. elegans Duchenne muscular dystrophy model. Proc Natl Acad Sci U S A. 2021:118.
36. Ellwood RA, Piasecki M, Szewczyk NJ. Caenorhabditis elegans as a model system for Duchenne muscular dystrophy. Int J Mol Sci. 2021;22:4891.
37. Moretti A, Fonteyne L, Giesert F, et al. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med. 2020;26:207-14.
38. Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:115-30.
39. Kamdar F, Das S, Gong W, et al. Stem cell-derived cardiomyocytes and beta-adrenergic receptor blockade in Duchenne muscular dystrophy cardiomyopathy. J Am Coll Cardiol. 2020;75:1159-74.
40. Dick E, Kalra S, Anderson D, et al. Exon skipping and gene transfer restore dystrophin expression in hiPSC-cardiomyocytes harbouring DMD mutations. Stem Cells Dev. ;2013:150127064140000.
41. Guan X, Mack DL, Moreno CM, et al. Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. Stem Cell Res. 2014;12:467-80.
42. Pioner JM, Guan X, Klaiman JM, et al. Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells. Cardiovasc Res. 2020;116:368-82.
43. Chang ACY, Pardon G, Chang ACH, et al. Increased tissue stiffness triggers contractile dysfunction and telomere shortening in dystrophic cardiomyocytes. Stem Cell Rep. 2021;16:2169-81.
44. Young CS, Hicks MR, Ermolova NV, et al. A Single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell. 2016;18:533-40.
45. Atmanli A, Chai AC, Cui M, et al. Cardiac Myoediting attenuates cardiac abnormalities in human and mouse models of Duchenne muscular dystrophy. Circ Res. 2021;129:602-16.
46. Min YL, Li H, Rodriguez-Caycedo C, et al. CRISPR-Cas9 corrects Duchenne muscular dystrophy Exon 44 deletion mutations in mice and human cells. Sci Adv. 2019;5:eaav4324.
47. Zhang Y, Li Y, Hu Q, et al. The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol. 2020;22:1332-45.
48. Eguchi A, Gonzalez AFGS, Torres-Bigio SI, et al. TRF2 rescues telomere attrition and prolongs cell survival in Duchenne muscular dystrophy cardiomyocytes derived from human iPSCs. Proc Natl Acad Sci U S A. 2023;120:e2209967120.
49. Hofbauer P, Jahnel SM, Papai N, et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell. 2021;184:3299-3317.e22.
50. Richards DJ, Coyle RC, Tan Y, et al. Inspiration from heart development: Biomimetic development of functional human cardiac organoids. Biomaterials. 2017;142:112-23.
51. Mavrommatis L, Jeong HW, Kindler U, et al. Human skeletal muscle organoids model fetal myogenesis and sustain uncommitted PAX7 myogenic progenitors. Elife. 2023:12.
52. Shahriyari M, Islam MR, Sakib SM, et al. Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy. J Cachexia Sarcopenia Muscle. 2022;13:3106-21.
53. ‘t Groen SLM, Franken M, Bock T, Krüger M, de Greef JC, Pijnappel WWMP. A knock down strategy for rapid, generic, and versatile modelling of muscular dystrophies in 3D-tissue-engineered-skeletal muscle. Skelet Muscle. 2024;14:3.
54. Long C, Li H, Tiburcy M, et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv. 2018;4:eaap9004.
55. Tejedera-Villafranca A, Montolio M, Ramón-Azcón J, Fernández-Costa JM. Mimicking sarcolemmal damagein vitro: a contractile 3D model of skeletal muscle for drug testing in Duchenne muscular dystrophy. Biofabrication. 2023;15:045024.
56. Sheikh O, Yokota T. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opin Investig Drugs. 2021;30:167-76.
57. Namgoong JH, Bertoni C. Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy. Degener Neurol Neuromuscul Dis. 2016;6:37-48.
58. Michorowska S. Ataluren-promising therapeutic premature termination codon readthrough frontrunner. Pharmaceuticals (Basel). 2021;14:785.
59. Wagner KR, Hamed S, Hadley DW, et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol. 2001;49:706-11.
60. Politano L. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update. Acta Myol. 2021;40:43-50.
61. Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T. The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol Ther. 2011;19:9-15.
62. Desjardins CA, Yao M, Hall J, et al. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res. 2022;50:11401-14.
63. Niks EH, Aartsma-Rus A. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2017;17:225-36.
64. Sang A, Zhuo S, Bochanis A, et al. Mechanisms of action of the US food and drug administration-approved antisense oligonucleotide drugs. BioDrugs. 2024;38:511-26.
67. Vincik LY, Dautel AD, Staples AA, et al. Evolving role of viltolarsen for treatment of Duchenne muscular dystrophy. Adv Ther. 2024;41:1338-50.
69. Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther. 2018;26:2337-56.
70. Le Guiner C, Servais L, Montus M, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.
71. Potter RA, Griffin DA, Heller KN, et al. Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy. Hum Gene Ther. 2021;32:375-89.
72. Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119:624-35.
73. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77:1122-31.
75. Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30:1364-80.
76. Le Hir M, Goyenvalle A, Peccate C, et al. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Mol Ther. 2013;21:1551-8.
77. Kachanov A, Kostyusheva A, Brezgin S, et al. The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution. Med Res Rev. 2024;44:2112-93.
78. Bönnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin immunity after gene therapy for Duchenne’s muscular dystrophy. N Engl J Med. 2023;388:2294-6.
79. Lek A, Atas E, Hesterlee SE, Byrne BJ, Bönnemann CG. Meeting report: 2022 muscular dystrophy association summit on ‘safety and challenges in gene transfer therapy’. J Neuromuscul Dis. 2023;10:327-36.
80. after high-dose rAAV9 gene therapy in a patient with Duchenne’s muscular dystrophy. N Engl J Med. 2023;389:2210-1.
81. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med. 2010;363:1429-37.
83. Xie Q, Chen X, Ma H, et al. Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor. EMBO Mol Med. 2024;16:945-65.
84. Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells. 2024;13:800.
85. Tabebordbar M, Zhu K, Cheng JKW, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016;351:407-11.
86. Long C, Amoasii L, Mireault AA, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351:400-3.
87. Porto EM, Komor AC, Slaymaker IM, Yeo GW. Base editing: advances and therapeutic opportunities. Nat Rev Drug Discov. 2020;19:839-59.
88. Chemello F, Chai AC, Li H, et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv 2021;7.
89. Ryu SM, Koo T, Kim K, et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat Biotechnol. 2018;36:536-9.
90. Lin J, Jin M, Yang D, et al. Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model. Nat Commun. 2024;15:5927.
91. Xu L, Zhang C, Li H, et al. Efficient precise in vivo base editing in adult dystrophic mice. Nat Commun. 2021;12:3719.
92. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149-57.
93. Lek A, Wong B, Keeler A et al. Unexpected death of a Duchenne muscular dystrophy patient in an N-of-1 trial of rAAV9-delivered CRISPR-transactivator. medRxiv. ;2023:2023.05.16.23289881.
94. Nitahara-Kasahara Y, Nakayama S, Kimura K, et al. Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy. Stem Cell Res Ther. 2023;14:108.
95. Xiao R, Zhou M, Wang P, et al. Full-length dystrophin restoration via targeted exon addition in DMD-patient specific iPSCs and cardiomyocytes. Int J Mol Sci. 2022;23:9176.
96. Lenardič A, Domenig SA, Zvick J, et al. Generation of allogeneic and xenogeneic functional muscle stem cells for intramuscular transplantation. J Clin Invest. 2024:134.
97. Dhoke NR, Kim H, Azzag K, Crist SB, Kiley J, Perlingeiro RCR. A novel CRISPR-Cas9 strategy to target DYSTROPHIN mutations downstream of Exon 44 in patient-specific DMD iPSCs. Cells. 2024;13:972.
98. McDonald CM, Marbán E, Hendrix S, et al. HOPE-2 Study Group. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399:1049-58.
99. Rogers RG, Fournier M, Sanchez L, et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice. JCI Insight. 2019;4:130202.
100. Budzynska K, Siemionow M, Stawarz K, Chambily L, Siemionow K. Chimeric cell therapies as a novel approach for Duchenne muscular dystrophy (DMD) and muscle regeneration. Biomolecules. 2024;14:575.
101. Tinsley JM, Blake DJ, Roche A, et al. Primary structure of dystrophin-related protein. Nature. 1992;360:591-3.
102. Szwec S, Kapłucha Z, Chamberlain JS, Konieczny P. Dystrophin- and utrophin-based therapeutic approaches for treatment of Duchenne muscular dystrophy: A comparative review. BioDrugs. 2024;38:95-119.
103. Li D, Bareja A, Judge L, et al. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J Cell Sci. 2010;123:2008-13.
104. Belanto JJ, Mader TL, Eckhoff MD, et al. Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci U S A. 2014;111:5723-8.
105. Miura P, Jasmin BJ. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol Med. 2006;12:122-9.
106. Falcucci L, Dooley CM, Adamoski D, et al. Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy. Nature. 2025;639:493-502.
107. Tinsley J, Deconinck N, Fisher R, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4:1441-4.
108. Wilkinson IVL, Perkins KJ, Dugdale H, et al. Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid. Angew Chem Int Ed Engl. 2020;59:2420-8.
109. Guiraud S, Squire SE, Edwards B, et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015;24:4212-24.
110. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 1996;384:349-53.
111. Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther. 2008;16:1539-45.
112. Liao HK, Hatanaka F, Araoka T, et al. In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. Cell. 2017;171:1495-1507.e15.
113. Sengupta K, Mishra MK, Loro E, Spencer MJ, Pyle AD, Khurana TS. Genome editing-mediated utrophin upregulation in Duchenne muscular dystrophy stem cells. Mol Ther Nucleic Acids. 2020;22:500-9.
114. Heier CR, Yu Q, Fiorillo AA, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019;2:e201800186.
115. Liu X, Wang Y, Gutierrez JS, et al. Disruption of a key ligand-H-bond network drives dissociative properties in Vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A. 2020;117:24285-93.
117. Tidball JG, Welc SS, Wehling‐Henricks M. Immunobiology of inherited muscular dystrophies. Compr Physiol. 2011;8:1313-56.
118. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet. 2009;18:482-96.
119. Perandini LA, Chimin P, Lutkemeyer DDS, Câmara NOS. Chronic inflammation in skeletal muscle impairs satellite cells function during regeneration: can physical exercise restore the satellite cell niche? FEBS J. 2018;285:1973-84.
120. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet. 2011;20:790-805.
121. Villalta SA, Rosenthal W, Martinez L, et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014;6:258ra142.
122. Rossi G, Antonini S, Bonfanti C, et al. Nfix regulates temporal progression of muscle regeneration through modulation of myostatin expression. Cell Re. ;14:2238-49.
123. Saclier M, Angelini G, Bonfanti C, Mura G, Temponi G, Messina G. Selective ablation of Nfix in macrophages attenuates muscular dystrophy by inhibiting fibro-adipogenic progenitor-dependent fibrosis. J Pathol. 2022;257:352-66.
124. Rossi G, Bonfanti C, Antonini S, et al. Silencing Nfix rescues muscular dystrophy by delaying muscle regeneration. Nat Commun. 2017;8:1055.
125. Babaeijandaghi F, Cheng R, Kajabadi N, et al. Metabolic reprogramming of skeletal muscle by resident macrophages points to CSF1R inhibitors as muscular dystrophy therapeutics. Sci Transl Med. 2022;14:eabg7504.
126. Colussi C, Mozzetta C, Gurtner A, et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A. 2008;105:19183-7.
128. Farini A, Tripodi L, Villa C, et al. Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin-deficient mice. EMBO Mol Med. 2023;15:e16244.
129. Kalkan H, Pagano E, Paris D, et al. Targeting gut dysbiosis against inflammation and impaired autophagy in Duchenne muscular dystrophy. EMBO Mol Med. 2023;15:e16225.
130. Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:124.
131. Sun M, Jiang W, Mu N, Zhang Z, Yu L, Ma H. Mitochondrial transplantation as a novel therapeutic strategy for cardiovascular diseases. J Transl Med. 2023;21:347.
132. Sun X, Gao R, Li W, et al. Alda-1 treatment promotes the therapeutic effect of mitochondrial transplantation for myocardial ischemia-reperfusion injury. Bioact Mater. 2021;6:2058-69.
133. Moskowitzova K, Shin B, Liu K, et al. Mitochondrial transplantation prolongs cold ischemia time in murine heart transplantation. J Heart Lung Transplant. 2019;38:92-9.
134. Ikeda G, Santoso MR, Tada Y, et al. Mitochondria-rich extracellular vesicles from autologous stem cell-derived cardiomyocytes restore energetics of ischemic myocardium. J Am Coll Cardiol. 2021;77:1073-88.
135. Masuzawa A, Black KM, Pacak CA, et al. Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2013;304:H966-82.
136. O’Brien CG, Ozen MO, Ikeda G, et al. Mitochondria-rich extracellular vesicles rescue patient-specific cardiomyocytes from doxorubicin injury: insights into the SENECA trial. JACC CardioOncol. 2021;3:428-40.
137. Lin RZ, Im GB, Luo AC, et al. Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature. 2024;629:660-8.
138. Yang X, Zhou P, Zhao Z, et al. Improvement effect of mitotherapy on the cognitive ability of Alzheimer’s Disease through NAD+/SIRT1-mediated autophagy. Antioxidants (Basel). 2023;12:2006.
139. Zhao J, Qu D, Xi Z, et al. Mitochondria transplantation protects traumatic brain injury via promoting neuronal survival and astrocytic BDNF. Transl Res. 2021;235:102-14.
140. Siemionow M, Bocian K, Bozyk KT, Ziemiecka A, Siemionow K. Chimeric cell therapy transfers healthy donor mitochondria in Duchenne muscular dystrophy. Stem Cell Rev Rep. 2024;20:1819-29.
141. Zhang A, Liu Y, Pan J, et al. Delivery of mitochondria confers cardioprotection through mitochondria replenishment and metabolic compliance. Mol Ther. 2023;31:1468-79.
142. Main EN, Cruz TM, Bowlin GL. Mitochondria as a therapeutic: a potential new frontier in driving the shift from tissue repair to regeneration. Regen Biomate. ;10:rbad070.
143. Zhao Z, Yu Z, Hou Y, Zhang L, Fu A. Improvement of cognitive and motor performance with mitotherapy in aged mice. Int J Biol Sci. 2020;16:849-58.
144. Kim MJ, Lee JM, Min K, Choi YS. Xenogeneic transplantation of mitochondria induces muscle regeneration in an in vivo rat model of dexamethasone-induced atrophy. J Muscle Res Cell Motil. 2024;45:53-68.
145. Wu Z, Chen L, Guo W, et al. Oral mitochondrial transplantation using nanomotors to treat ischaemic heart disease. Nat Nanotechnol. 2024;19:1375-85.
146. Alexander JF, Seua AV, Arroyo LD, et al. Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits. Theranostics. 2021;11:3109-30.
147. Hughes MC, Ramos SV, Turnbull PC, et al. Impairments in left ventricular mitochondrial bioenergetics precede overt cardiac dysfunction and remodelling in Duchenne muscular dystrophy. J Physiol. 2020;598:1377-92.
148. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629-56.
149. Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12:763-71.
150. Li B, Xiong W, Liang WM, Chiou JS, Lin YJ, Chang ACY. Targeting of CAT and VCAM1 as novel therapeutic targets for DMD cardiomyopathy. Front Cell Dev Biol. 2021;9:659177.
151. Kyrychenko V, Poláková E, Janíček R, Shirokova N. Mitochondrial dysfunctions during progression of dystrophic cardiomyopathy. Cell Calcium. 2015;58:186-95.
152. Dubinin MV, Talanov EY, Tenkov KS, Starinets VS, Mikheeva IB, Belosludtsev KN. Transport of Ca2+ and Ca2+-dependent permeability transition in heart mitochondria in the early stages of Duchenne muscular dystrophy. Biochim Biophys Acta Bioenerg. 2020;1861:148250.
153. Willi L, Abramovich I, Fernandez-Garcia J, et al. Bioenergetic and metabolic impairments in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. Int J Mol Sci. 2022;23:9808.
154. Kuno A, Hosoda R, Sebori R, et al. Resveratrol ameliorates mitophagy disturbance and improves cardiac pathophysiology of dystrophin-deficient mdx mice. Sci Rep. 2018;8:15555.
155. Pauly M, Daussin F, Burelle Y, et al. AMPK activation stimulates autophagy and ameliorates muscular dystrophy in the mdx mouse diaphragm. Am J Pathol. 2012;181:583-92.
156. Ljubicic V, Jasmin BJ. Metformin increases peroxisome proliferator-activated receptor γ Co-activator-1α and utrophin a expression in dystrophic skeletal muscle. Muscle Nerve. 2015;52:139-42.
157. Ljubicic V, Burt M, Lunde JA, Jasmin BJ. Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis. Am J Physiol Cell Physiol. 2014;307:C66-82.
158. Hollinger K, Shanely RA, Quindry JC, Selsby JT. Long-term quercetin dietary enrichment decreases muscle injury in mdx mice. Clin Nutr. 2015;34:515-22.
159. Suntar I, Sureda A, Belwal T, et al. Natural products, PGC-1 α , and Duchenne muscular dystrophy. Acta Pharm Sin B. 2020;10:734-45.
160. Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96:253-305.
161. Kyrychenko S, Poláková E, Kang C, et al. Hierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathy. Cardiovasc Res. 2013;97:666-75.
162. Fauconnier J, Thireau J, Reiken S, et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 2010;107:1559-64.
163. Zhang SS, Zhou S, Crowley-McHattan ZJ, Wang RY, Li JP. A review of the role of endo/sarcoplasmic reticulum-mitochondria Ca2+ transport in diseases and skeletal muscle function. Int J Environ Res Public Health. 2021;18:3874.
165. Santulli G, Xie W, Reiken SR, Marks AR. Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci U S A. 2015;112:11389-94.
166. Zabłocka B, Górecki DC, Zabłocki K. Disrupted calcium homeostasis in Duchenne muscular dystrophy: a common mechanism behind diverse consequences. Int J Mol Sci. 2021;22:11040.
167. Souidi M, Resta J, Dridi H, et al. Ryanodine receptor dysfunction causes senescence and fibrosis in Duchenne dilated cardiomyopathy. J Cachexia Sarcopenia Muscle. 2024;15:536-51.
168. Goonasekera SA, Lam CK, Millay DP, et al. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest. 2011;121:1044-52.
169. Kodippili K, Hakim CH, Burke MJ, et al. SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model. Mol Ther Methods Clin Dev. 2024;32:101268.
170. Balakrishnan R, Mareedu S, Babu GJ. Reducing sarcolipin expression improves muscle metabolism in mdx mice. Am J Physiol Cell Physiol. 2022;322:C260-74.
171. Liu Z, Cai H, Dang Y, Qiu C, Wang J. Adenosine triphosphate-sensitive potassium channels and cardiomyopathies (review). Mol Med Rep. 2016;13:1447-54.
172. Graciotti L, Becker J, Granata AL, Procopio AD, Tessarollo L, Fulgenzi G. Dystrophin is required for the normal function of the cardio-protective KATP channel in cardiomyocytes. PLoS One. 2011;6:e27034.
173. Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet. 2004;36:382-7.
174. Farid TA, Nair K, Massé S, et al. Role of KATP channels in the maintenance of ventricular fibrillation in cardiomyopathic human hearts. Circ Res. 2011;109:1309-18.
175. Rubi L, Koenig X, Kubista H, Todt H, Hilber K. Decreased inward rectifier potassium current IK1 in dystrophin-deficient ventricular cardiomyocytes. Channels (Austin). 2017;11:101-8.
176. Pacioretty LM, Cooper BJ, Gilmour RF Jr. Reduction of the transient outward potassium current in canine X-linked muscular dystrophy. Circulation. 1994;90:1350-6.
177. Fatima S, Zhou H, Chen Y, Liu Q. Role of ferroptosis in the pathogenesis of heart disease. Front Physiol. 2024;15:1450656.
178. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010;56:1001-12.
179. Wansapura JP, Hor KN, Mazur W, et al. Left ventricular T2 distribution in Duchenne muscular dystrophy. J Cardiovasc Magn Reson. 2010;12:14.
180. Andrysiak K, Machaj G, Priesmann D, et al. Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment. Cardiovasc Res. 2024;120:69-81.
181. Furihata T, Takada S, Kakutani N, et al. Cardiac-specific loss of mitoNEET expression is linked with age-related heart failure. Commun Biol. 2021;4:138.
182. Alves FM, Kysenius K, Caldow MK, et al. Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2022;13:1541-53.
183. Bizot F, Goossens R, Tensorer T, et al. Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice. Mol Ther Nucleic Acids. 2022;30:606-20.
184. Barthélémy F, Wang RT, Hsu C, et al. Targeting RyR activity boosts antisense exon 44 and 45 skipping in human DMD skeletal or cardiac muscle culture models. Mol Ther Nucleic Acids. 2019;18:580-9.
185. Kendall GC, Mokhonova EI, Moran M, et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med. 2012;4:164ra160.
186. Hayashita-Kinoh H, Guillermo PH, Nitahara-Kasahara Y, et al. Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment. Mol Ther Methods Clin Dev. 2021;20:133-41.
187. Mishra MK, Loro E, Sengupta K, Wilton SD, Khurana TS. Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction. PLoS One. 2017;12:e0182676.
188. Cacchiarelli D, Incitti T, Martone J, et al. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep. 2011;12:136-41.
189. Peccate C, Mollard A, Le Hir M, et al. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum Mol Genet. 2016;25:3555-63.
190. Blitek M, Gastaldi C, Doisy M, et al. Combined 20-hydroxyecdysone and antisense-mediated exon skipping improve functional outcomes in a mouse model of Duchenne muscular dystrophy. Nucleic Acid Ther. 2025; doi: 10.1089/nat.2024.0085.
191. Cervia D, Zecchini S, Pincigher L, et al. Oral administration of plumbagin is beneficial in in vivo models of Duchenne muscular dystrophy through control of redox signaling. Free Radic Biol Med. 2024;225:193-207.
192. Villa C, Secchi V, Macchi M, et al. Magnetic-field-driven targeting of exosomes modulates immune and metabolic changes in dystrophic muscle. Nat Nanotechnol. 2024;19:1532-43.
